CRISPR-Cas9 is a reprogrammable DNA cutting machine that is being used to edit genomes in many organisms for research purposes. Its primary component, the Cas9 enzyme (orange), cuts genomic DNA ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

总之，SpG和SpRY能一同用CRISPR-Cas9核酸酶对几乎整个基因组进行不受限设靶，并具有单碱基对的精度。应用SpRY，作者能够纠正与人类疾病相关的突变 ...

CRISPR-Cas systems have been exploited for targeted genome editing. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging due to its high off-target activity.

CRISPR-Cas9 editing leads to widespread loss of the targeted chromosome in human T cells, but scientists recently discovered a way to prevent such loss. To investigate how Cas9 gene editing affected T ...

Dr. Xiao’s research focuses on developing genomic technologies and applying them in studying the human genome. Among his recent work at Drexel is the development of technologies based on the ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.